Tenaya Therapeutics, Inc. (NASDAQ:TNYA – Free Report) – Investment analysts at Leerink Partnrs lifted their Q1 2024 earnings per share estimates for shares of Tenaya Therapeutics in a research report issued on Thursday, February 8th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($0.47) per share for the quarter, up from their previous estimate of ($0.53). Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.69) per share. Leerink Partnrs also issued estimates for Tenaya Therapeutics’ Q3 2024 earnings at ($0.47) EPS, FY2024 earnings at ($1.99) EPS and FY2025 earnings at ($1.99) EPS.
Separately, SVB Leerink initiated coverage on shares of Tenaya Therapeutics in a research note on Thursday, November 30th. They issued an “outperform” rating and a $7.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $15.80.
Check Out Our Latest Stock Analysis on TNYA
Tenaya Therapeutics Price Performance
Shares of NASDAQ TNYA opened at $5.68 on Monday. Tenaya Therapeutics has a 1 year low of $1.66 and a 1 year high of $8.09. The company has a market capitalization of $386.86 million, a price-to-earnings ratio of -3.02 and a beta of 2.50. The business has a 50-day moving average of $3.30 and a two-hundred day moving average of $3.05.
Hedge Funds Weigh In On Tenaya Therapeutics
A number of institutional investors have recently modified their holdings of TNYA. Bailard Inc. acquired a new stake in Tenaya Therapeutics during the 4th quarter worth $107,000. Cornercap Investment Counsel Inc. boosted its stake in shares of Tenaya Therapeutics by 136.2% during the fourth quarter. Cornercap Investment Counsel Inc. now owns 81,255 shares of the company’s stock worth $263,000 after buying an additional 46,847 shares during the period. Redwood Wealth Management Group LLC grew its holdings in shares of Tenaya Therapeutics by 38.0% during the fourth quarter. Redwood Wealth Management Group LLC now owns 16,350 shares of the company’s stock worth $53,000 after buying an additional 4,500 shares during the last quarter. SG Americas Securities LLC increased its position in Tenaya Therapeutics by 20.0% in the 4th quarter. SG Americas Securities LLC now owns 25,337 shares of the company’s stock valued at $82,000 after acquiring an additional 4,224 shares during the period. Finally, Vanguard Group Inc. raised its stake in Tenaya Therapeutics by 8.4% during the 3rd quarter. Vanguard Group Inc. now owns 2,167,868 shares of the company’s stock valued at $5,528,000 after acquiring an additional 168,489 shares during the last quarter. 70.22% of the stock is owned by institutional investors and hedge funds.
About Tenaya Therapeutics
Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy; TN-301, a small molecule for heart failure with preserved ejection fraction; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy.
Read More
Receive News & Ratings for Tenaya Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Tenaya Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
ABMN Staff
Source link
